Tagged Articles

reactions 52 articles

Improper exposure to, use of Testosterone drugs can be harmful

The sharp upswing in sales of Androgel,Testim and other hormone-replacement drugs in recent years indicates record numbers of American men are seeking a boost in their testosterone levels. But while men who use these drugs may experience some relief from age-related declines in strength and libido, among other benefits, the drugs may also work behind the scenes to create a number of harmful side effects that may not be so easily or readily noticeable at first. Some of the most commonly reported side effects of topical testosterone drugs, which are usually applied to the shoulders, upper arms, or abdomen, are ... Read More

New study links Actos and Avandia to vision problems

A new study published in The Archives of Internal Medicine has found that patients taking thiazolidinediones, a class of type 2 diabetes drugs that includes Actos and Avandia, may be at a higher risk of developing vision problems. The study monitored more than 103,000 patients with type 2 diabetes over a period of about 10 years. Researchers found that those who took either Actos or Avandia had a risk of developing macular edema two to three times higher than those who didn’t use the popular drugs. The eye disorder occurs when protein deposits collect on or under the central part ... Read More

Johnson & Johnson’s new diabetes drug shows promise in late-stage clinical trials

A new experimental drug made by Johnson & Johnson has demonstrated a better ability to lower blood sugar levels in patients with diabetes than Merck’s Januvia and the older, more conventional drug glimepiride, data from a couple of late-stage clinical trials of the drug have shown. Results of the studies, which were conducted over 52 weeks and involved more than 10,000 patients, also found the new Johnson & Johnson drug, canagliflozin, contributed to weight loss in patients better than Januvia and glimepiride (marketed as Amaryl and GLIMY) and was linked to fewer incidents of hypoglycemia, a dangerous drop in blood ... Read More

Study blames surge in testosterone drug sales on “disease mongering” marketing

Testosterone replacement drugs are surging in popularity in Australia and Canada, thanks to slick promotional campaigns and “disease mongering” by pharmaceutical companies, said the author of a new study published in the Medical Journal of Australia (MJA). In the study, David Handelsman, director of the ANZAC Research Institute at the University of Sydney, examined patterns in testosterone drug prescribing in Australia from 1992 to 2010. He found total expenditures on testosterone prescriptions more than doubled in that time period after taking into account inflation and population growth, yet there was no correlating increase in the number of approved uses for ... Read More

Canadian study finds Actos doubles bladder cancer risk

Patients who take the diabetes drug Actos (pioglitazone) two years or longer are twice as likely to develop bladder cancer than those who haven’t taken the drug, Canadian researchers have found. The Canadian study, led by Montreal epidemiologist Dr. Laurent Azoulay and published online in the British Medical Journal, analyzed the medical records of nearly 116,000 patients in Great Britain newly treated with diabetes drugs between 1988 and 2009. The records were consolidated in Great Britain’s General Practice Database from about 600 general practices in that country. The researchers found that while absolute risk of developing bladder cancer was relatively ... Read More

Testim maker poised to expand its share of men’s health market

Bolstered by soaring demand for testosterone replacement products, a deal with GlaxoSmithKline to market its top drug Testim, and now favorable results of a new drug study to treat penile curvature, things are looking up for Auxilium Pharmaceuticals. Reuters reports that shares of Auxilium, a small drug company based in Malvern, Pennsylvania, shot up 17 percent Monday on news that two late-stage trials indicated its drug Xiaflex reduced curvature of the penis by more than 30 percent in men with Peyronie’s Disease, a condition caused when excessive collagen protein deposits create curvature and sometimes painful erections. Xiaflex is already approved ... Read More

Testim maker files patent infringement lawsuit

Auxilium Pharmaceuticals, the maker of Testim® 1%, has filed a lawsuit against Watson Laboratories Inc. and related companies for allegedly violating patents protecting its best-selling testosterone replacement gel. Auxilium and FCB I LLC, a subsidiary of Xstelos Holdings Inc., filed the lawsuit in U.S. District Court for the District of New Jersey on May 23, accusing Watson Laboratories, Watson Pharmaceuticals, Inc. and Watson Pharma Inc. of infringing on 10 Testim® patents listed in the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations, better known in the industry as the FDA’s “Orange Book.” According to Auxilium, the ... Read More

Testosterone wars heat up as Testim maker allies with GlaxoSmithKline

Testim manufacturer Auxilium Pharmaceuticals Inc. of Malvern, Pennsylvania, has entered a partnership with GlaxoSmithKline to drive up sales of the testosterone drug, the companies announced this week. Testim is a topical gel containing one percent testosterone, prescribed as a hormone-replacement therapy for men with clinically low testosterone levels and the physical slow-down that generally accompanies “low T,” as the condition is sometimes called. Testim and other testosterone replacement therapies are also sought after by men who take the drug for recreational purposes. The effects of excessive testosterone in men are virtually the same as taking steroids, with increased muscle mass ... Read More

Actos drugmaker consolidates its California facilities

Japanese drugmaker Takeda, whose diabetes drug Actos faces patent expiration, declining sales, and mounting personal injury lawsuits, is closing its San Francisco research facilities, the San Francisco Business Times reports. Takeda’s San Francisco research operations once played a key role in the company’s development of early-stage antibody drugs. The drugmaker announced late last year that it would be consolidating its California-based facilities, but did not disclose how the move would affect the San Francisco site. According to the Business Times, Mary Haak-Frendscho, president of Takeda San Francisco, recently took a job as executive chairman of a San Francisco-based Compugen Ltd. ... Read More

Actos patent expiration sets Takeda on acquisitions hunt

Faced with sharply dwindling profits, Japan’s Takeda Pharmaceutical Co. has gone on an international shopping spree in search of drug company acquisitions that would introduce new drugs to the Takeda line and help offset a cash crunch brought about by the patent expiration on its diabetes drug Actos and other key drugs. Takeda, the largest pharmaceutical company in Asia, has spent almost $15 billion in overseas acquisitions in less than two years and has its sights set on other companies that could give it a needed boost. Last year, the company paid $13.7 million for the Swiss company Nycomed, which ... Read More